Journal article
Abstract 5045: NTSR1-targeted alpha therapeutic [Ac-225]-FPI-2059 induces growth inhibition in a preclinical colorectal tumor model
Abstract
Abstract
Background: Neurotensin receptor 1 (NTSR1) is overexpressed in multiple cancer indications that include pancreatic, colorectal and prostate cancers, all of which have limited therapeutic treatment options and unmet medical need. Fusion is developing novel targeted alpha therapeutics (TATs) that enable the specific delivery of high energy alpha particles (actinium-225; [225Ac]) to tumor cells while sparing surrounding …
Authors
Mahammad S; Broqueza J; Theriault BL; Forbes J; Leamon CP; Valliant J
Journal
Cancer Research, Vol. 83, No. 7_Supplement, pp. 5045–5045
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 4, 2023
DOI
10.1158/1538-7445.am2023-5045
ISSN
0008-5472